Advertisement
GKOS or NTRA or VCYT
Which Stock Would AI Choose? Glaukos Corporation (GKOS) vs. Natera, Inc. (NTRA) vs. Veracyte, Inc. (VCYT) Stock Comparison
Key Takeaways
- GKOS delivered a Q1 revenue beat with 58% U.S. glaucoma sales growth, prompting raised full-year guidance and a post-earnings share surge.
- NTRA exhibits robust momentum with shares near $207 and a $29 billion market cap, supported by strong test volume growth and positive analyst targets around $253.
- VCYT trades around $33 with analyst targets suggesting 32% upside to $44, amid steady genomic diagnostics demand despite recent share pressure.
- In recent market activity, GKOS rose over 13% monthly while NTRA shows year-to-date strength; VCYT lags but holds valuation appeal.
- All three operate in precision healthcare but differ in focus: devices for GKOS, cell-free DNA for NTRA, and genomic classifiers for VCYT.
Introduction
Glaukos Corporation (GKOS), Natera, Inc. (NTRA), and Veracyte, Inc. (VCYT) represent key players in the precision healthcare sector, blending medical devices and genomic diagnostics. This stock comparison evaluates their recent performance, growth drivers, and market positioning amid evolving demand for innovative therapies and tests. Growth-oriented traders and investors tracking healthcare trends—particularly in oncology, ophthalmology, and genetic screening—may find value in assessing relative momentum, revenue trajectories, and sentiment shifts in this competitive space.
GKOS Overview and Recent Performance
Glaukos Corporation (GKOS) develops ophthalmic medical technologies, primarily micro-surgical implants for glaucoma treatment. In recent quarters, the company reported Q1 revenue of $150.6 million, surpassing estimates by 10%, fueled by 58% growth in U.S. glaucoma franchise sales. Shares surged post-earnings on raised full-year guidance, with monthly gains exceeding 13% despite weekly volatility. Sentiment has improved on strong execution and pipeline progress, though ongoing EPS (earnings per share) losses reflect R&D investments. Trading near $140, GKOS benefits from sector tailwinds in minimally invasive procedures.
NTRA Overview and Recent Performance
Natera, Inc. (NTRA) specializes in cell-free DNA testing, including the Signatera platform for cancer recurrence monitoring and prenatal screening. Recent financials show robust test volume expansion, with Q4 2025 processing over 923,600 tests, up significantly year-over-year. Shares trade around $207, supported by a $29 billion market cap and analyst targets near $253, implying 22% upside. Positive EPS beats, like Q4's $0.36 versus expectations, have bolstered momentum amid growing adoption in oncology. Recent market activity reflects sustained investor confidence in NTRA's scalable model, despite high valuations.
VCYT Overview and Recent Performance
Veracyte, Inc. (VCYT) focuses on genomic diagnostics, offering tests like Afirma for thyroid cancer risk assessment. The company maintains steady revenue growth in its core segments, with recent quarters showing improved test accessioning. Shares hover near $33, with consensus targets at $44, suggesting over 30% potential upside. While facing short-term pressure, including a 15% drop since last earnings, VCYT benefits from expanding genomic sequencing demand. Performance reflects broader sector dynamics, with focus on profitability improvements offsetting competitive risks.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 AI trading bots from a library of 351, selecting only those excelling in current market conditions across thousands of tickers. These bots showcase annualized returns ranging from +23% to +162%, win rates of 51% to 88%, and profit factors up to 11.70, employing diverse strategies like trend trading, multi-agents, and TP/SL (take-profit/stop-loss) corridors on timeframes from 5 minutes to 60 minutes. Examples include bots targeting semiconductors (e.g., NVDA, AMD) with 96% returns or infrastructure plays with low drawdowns. Traders can explore these high performers for various styles and explore copying signals tailored to volatile markets.
Head-to-Head Comparison
GKOS, NTRA, and VCYT share healthcare exposure but diverge in models: GKOS' device-centric approach yields high-margin glaucoma sales, contrasting NTRA and VCYT's lab-based testing. Growth drivers favor NTRA's volume surge, while GKOS shows superior recent momentum. Risks include R&D losses across all, with VCYT most sensitive to reimbursement changes. Valuation-wise, VCYT appears cheapest relative to targets; NTRA commands premium on scale. Sentiment tilts toward NTRA's stability versus peers' volatility.
Tickeron AI Verdict
Tickeron's AI currently leans toward NTRA for its consistent test growth, market-leading cap, and upward analyst revisions, positioning it favorably amid healthcare tailwinds. While GKOS's revenue beats signal upside and VCYT offers value, NTRA's trend stability enhances probability of outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GKOS’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 0 green FA rating(s), and VCYT’s FA Score reflects 0 green FA rating(s).
- GKOS’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GKOS’s TA Score shows that 5 TA indicator(s) are bullish while NTRA’s TA Score has 5 bullish TA indicator(s), and VCYT’s TA Score reflects 5 bullish TA indicator(s).
- GKOS’s TA Score: 5 bullish, 4 bearish.
- NTRA’s TA Score: 5 bullish, 4 bearish.
- VCYT’s TA Score: 5 bullish, 5 bearish.
Price Growth
GKOS (@Medical/Nursing Services) experienced а +2.20% price change this week, while NTRA (@Medical Specialties) price change was -1.24% , and VCYT (@Medical Specialties) price fluctuated +19.96% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.80%. For the same industry, the average monthly price growth was -1.65%, and the average quarterly price growth was -4.18%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.15%. For the same industry, the average monthly price growth was +0.16%, and the average quarterly price growth was -7.90%.
Reported Earning Dates
GKOS is expected to report earnings on Aug 05, 2026.
NTRA is expected to report earnings on Jul 30, 2026.
VCYT is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.80% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-1.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| GKOS | NTRA | VCYT | |
| Capitalization | 8.01B | 29.2B | 3.16B |
| EBITDA | -144M | -227.7M | 112M |
| Gain YTD | 20.769 | -10.860 | -6.057 |
| P/E Ratio | N/A | N/A | 36.62 |
| Revenue | 551M | 2.5B | 542M |
| Total Cash | 277M | 1.09B | 439M |
| Total Debt | 103M | 240M | 39.3M |
GKOS | NTRA | VCYT | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 19 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 59 Fair valued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 66 | 49 | 100 | |
SMR RATING 1..100 | 96 | 94 | 79 | |
PRICE GROWTH RATING 1..100 | 40 | 53 | 43 | |
P/E GROWTH RATING 1..100 | 58 | 100 | 93 | |
SEASONALITY SCORE 1..100 | 90 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (59) in the Biotechnology industry is in the same range as VCYT (65) in the Biotechnology industry, and is somewhat better than the same rating for GKOS (94) in the Medical Specialties industry. This means that NTRA's stock grew similarly to VCYT’s and somewhat faster than GKOS’s over the last 12 months.
NTRA's Profit vs Risk Rating (49) in the Biotechnology industry is in the same range as GKOS (66) in the Medical Specialties industry, and is somewhat better than the same rating for VCYT (100) in the Biotechnology industry. This means that NTRA's stock grew similarly to GKOS’s and somewhat faster than VCYT’s over the last 12 months.
VCYT's SMR Rating (79) in the Biotechnology industry is in the same range as NTRA (94) in the Biotechnology industry, and is in the same range as GKOS (96) in the Medical Specialties industry. This means that VCYT's stock grew similarly to NTRA’s and similarly to GKOS’s over the last 12 months.
GKOS's Price Growth Rating (40) in the Medical Specialties industry is in the same range as VCYT (43) in the Biotechnology industry, and is in the same range as NTRA (53) in the Biotechnology industry. This means that GKOS's stock grew similarly to VCYT’s and similarly to NTRA’s over the last 12 months.
GKOS's P/E Growth Rating (58) in the Medical Specialties industry is somewhat better than the same rating for VCYT (93) in the Biotechnology industry, and is somewhat better than the same rating for NTRA (100) in the Biotechnology industry. This means that GKOS's stock grew somewhat faster than VCYT’s and somewhat faster than NTRA’s over the last 12 months.
| GKOS | NTRA | VCYT | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | N/A | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 76% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 78% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 75% | 1 day ago 76% | N/A |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 77% | 1 day ago 76% |
| TrendMonth ODDS (%) | 1 day ago 75% | 1 day ago 82% | 1 day ago 80% |
| Advances ODDS (%) | 1 day ago 78% | 1 day ago 80% | 10 days ago 73% |
| Declines ODDS (%) | 6 days ago 67% | 15 days ago 78% | 1 day ago 79% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 72% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 84% | 1 day ago 81% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPUS | 135.85 | -0.01 | N/A |
| JPMorgan Diversified Return US Eq ETF | |||
| PMSE | 26.05 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF - September | |||
| BOAT | 42.53 | -0.03 | -0.07% |
| SonicShares™ Global Shipping ETF | |||
| APXM | 31.55 | -0.03 | -0.08% |
| FT Vest U.S. Equity Max Buffr ETF - Apr | |||
| FV | 69.59 | -0.19 | -0.27% |
| First Trust Dorsey Wright Focus 5 ETF | |||
GKOS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GKOS has been loosely correlated with ISRG. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GKOS jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To GKOS | 1D Price Change % | ||
|---|---|---|---|---|
| GKOS | 100% | +0.73% | ||
| ISRG - GKOS | 51% Loosely correlated | +2.81% | ||
| NTRA - GKOS | 48% Loosely correlated | +2.55% | ||
| RDNT - GKOS | 48% Loosely correlated | +0.18% | ||
| TWST - GKOS | 46% Loosely correlated | -0.46% | ||
| ALGN - GKOS | 43% Loosely correlated | +0.72% | ||
More | ||||